Bioinputs

Biologicals Gain Ground as Farmers Demand Stronger Proof of Performance and ROI

Biologicals continue expanding across U.S. agriculture, but farmers are raising the bar on performance, consistency and return before committing.

Daniel Whitmore
Daniel Whitmore is a U.S.-based journalist covering agricultural markets, biotechnology, crop protection, and seed innovation, with a focus on how these technologies are shaping global food systems.

Biological products are gaining ground across U.S. agriculture in 2026, but farmers are becoming more demanding about what earns a place in their crop programs. A survey analyzed by AgroLatam involving 90 valid responses from agricultural retailers, cooperatives, crop consultants, suppliers and manufacturers found that 39% identify lack of trust in product performance as the biggest barrier to wider biological adoption. Only 19% point to biologicals being too expensive, while 16% believe conventional products still perform better. The findings suggest that the next phase of growth may depend less on novelty and more on proving consistent agronomic and economic value.

The survey provides a particularly relevant snapshot of U.S. row-crop agriculture. Eighty-six percent of respondents were agricultural retailers, cooperatives or crop consultants, while 8% represented fertilizer producers or suppliers and 6% manufacturers or formulators. The Midwest accounted for 43% of responses, and the crop footprint was heavily concentrated in corn, served by 97% of respondents; soybeans, 82%; and wheat, 62%. That makes the findings especially useful for understanding how biologicals are moving from trials toward broader commercial programs in major U.S. crops.

Biologicals are increasingly being evaluated alongside conventional crop protection and fertility tools in major U.S. row crops.

Biologicals are increasingly being evaluated alongside conventional crop protection and fertility tools in major U.S. row crops.

Price Matters, but Farmers Are Asking for More

Cost remains part of the conversation, but the numbers show that price is not the industry's largest adoption challenge. While 19% of respondents say biologicals are too expensive compared with conventional products for regular use, more than twice as many - 39% - identify lack of trust in performance as the main obstacle. Another 16% believe conventional products work better. For biological manufacturers and agricultural retailers, that distinction matters: lowering the price alone may not unlock adoption if growers remain uncertain about efficacy, repeatability and economic return.

What Is Holding Back Wider Biological Adoption?

Main barrierShareMarket signal
Lack of trust in performance39%More field evidence is needed
Biologicals are too expensive19%ROI must justify the investment
Conventional products work better16%Performance remains under comparison
   Source: 2026 U.S. industry survey, 90 responses.

The current farm economy helps explain that scrutiny. With growers protecting margins and evaluating input spending more carefully, technologies increasingly have to demonstrate whether they can protect yield, improve nutrient efficiency, reduce production risk or deliver another measurable economic benefit. Participants describe a divided market: some growers are cutting anything considered nonessential, while others continue investing in tools that have already demonstrated an ability to protect yield potential. Biologicals have an opportunity in the latter group, but repeatable results are becoming critical.

 As biological portfolios expand, field trials and repeatable agronomic data are becoming increasingly important in determining which products gain broader adoption.

Biostimulants currently have the strongest commercial position. They represented 50% of biological sales reported by survey participants, compared with 32% for biofertilizers and 18% for biopesticides. At the retail level, 84% of respondents offer biostimulants, 54% sell biofertilizers and 30% carry biopesticides. The longer-term movement is also notable: the share offering biostimulants increased from 73% in 2023 to 84% in 2026, while biopesticides climbed from 19% to 30%.

Biostimulants Lead the Biological Market

SegmentShare of biological salesRespondents offering products
Biostimulants50%84%
Biofertilizers32%54%
Biopesticides18%30%
   Source: 2026 U.S. industry survey, 90 responses.

Another finding provides an important clue about where the market is heading. Ninety-eight percent of respondents say their grower-customers typically use biologicals as supplements to conventional crop inputs, while just 2% report their use as stand-alone replacements. That suggests the near-term opportunity is not necessarily a biological-versus-chemistry competition. Instead, biologicals are increasingly being evaluated as another component of integrated crop programs that combine crop protection, fertility, seed treatment and biological technologies.

How Farmers Are Using Biologicals

ApproachShareMarket direction
Supplement to conventional products98%Dominant approach
Stand-alone replacement2%Still marginal
Broader directionIntegrationBiology + nutrition + crop protection
   Source: 2026 U.S. agricultural industry survey.

Latin America Offers a Glimpse of How Far Adoption Can Go

The trend is not limited to the United States. Latin America and the Caribbean is currently the world's fastest-growing region for bioinput use, with estimated annual growth above 10%, according to a July 2026 analysis from the UN Food and Agriculture Organization. FAO reports that an average of 38% of farmers globally have adopted biostimulants, biofertilizers or biocontrol products, while Brazil's adoption rate has reached 67%, placing one of the world's largest soybean and corn producers among the leading markets for these technologies.

For most growers, biologicals are being integrated as complementary tools rather than stand-alone replacements for conventional inputs.

For most growers, biologicals are being integrated as complementary tools rather than stand-alone replacements for conventional inputs.

That Latin American experience also adds an economic dimension to the U.S. discussion. FAO examined different bioinput adoption and production scenarios in Argentina, Bolivia, Brazil, Costa Rica and Mexico. In specific cases involving sugarcane in Mexico and soybeans and grapes in Bolivia, integrating commercial biological inputs into conventional systems while partially reducing agrochemical use improved profitability through higher yields or lower production costs. FAO cautions that those results cannot be generalized: returns vary with crop, soil, agroecological conditions, production scale and technology.

The region also illustrates why biologicals are increasingly being discussed beyond sustainability. Latin American agriculture remains highly exposed to international fertilizer and energy markets. FAO reported that the value of fertilizer imports into Latin America and the Caribbean jumped 137% in 2022, helping intensify interest in alternatives capable of improving nutrient efficiency and reducing exposure to external supply shocks. More recently, renewed uncertainty around global fertilizer trade has kept that strategic question alive.

For U.S. companies, the comparison is particularly relevant because the two agricultural regions share major crops - including soybeans and corn - while increasingly participating in the same biological technology ecosystem. Latin America's rapid adoption does not mean its experience can be transferred directly to U.S. farms, but it demonstrates that biologicals can reach significant commercial scale when agronomic performance, economics, distribution and farmer confidence align.

Back in the U.S., expectations remain clearly expansionary. Eighty percent of survey respondents plan to increase the number of biological products they sell over the coming year, 16% expect to maintain their current level and only 4% anticipate a decrease. That creates an unusual market dynamic: more products are entering the channel at the same time farmers are becoming more selective about which technologies deserve their investment.

For biological manufacturers, retailers and growers, the message emerging in 2026 is therefore increasingly clear. The question is shifting from whether biologicals can become part of mainstream agriculture to which products can consistently earn their place in the program. Price will remain important, but performance, repeatability, compatibility and measurable ROI are likely to determine which biological technologies move from a trial on a few acres to recurring use across the farm.

© AgroLatam. All rights reserved.
Esta nota habla de: